Clinical Trial Update: Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

View source ↗

Summary

A completed post-marketing study evaluating CT-P13 (infliximab) for standard of care treatment in inflammatory bowel diseases, including ulcerative colitis and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• CT-P13 (infliximab biosimilar)

Snippet

Sponsor: Pfizer | Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis | Status: COMPLETED | Results posted: 2020-02-13